| 000 | 01631 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250515155724.0 | ||
| 264 | 0 | _c20090320 | |
| 008 | 200903s 0 0 eng d | ||
| 022 | _a0340-6245 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHammerstingl, Christoph | |
| 245 | 0 | 0 |
_aHow useful is determination of anti-factor Xa activity to guide bridging therapy with enoxaparin? A pilot study. _h[electronic resource] |
| 260 |
_bThrombosis and haemostasis _cFeb 2009 |
||
| 300 |
_a325-32 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAnticoagulants _xadministration & dosage |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 |
_aDrug Monitoring _xmethods |
| 650 | 0 | 4 |
_aEnoxaparin _xadministration & dosage |
| 650 | 0 | 4 | _aFactor Xa Inhibitors |
| 650 | 0 | 4 |
_aHemorrhage _xchemically induced |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInternational Normalized Ratio |
| 650 | 0 | 4 | _aLinear Models |
| 650 | 0 | 4 | _aLogistic Models |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPartial Thromboplastin Time |
| 650 | 0 | 4 |
_aPhenprocoumon _xadministration & dosage |
| 650 | 0 | 4 | _aPilot Projects |
| 650 | 0 | 4 | _aPredictive Value of Tests |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 |
_aSurgical Procedures, Operative _xadverse effects |
| 650 | 0 | 4 |
_aThromboembolism _xetiology |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aOmran, Heyder | |
| 700 | 1 | _aTripp, Christian | |
| 700 | 1 | _aPoetzsch, Bernd | |
| 773 | 0 |
_tThrombosis and haemostasis _gvol. 101 _gno. 2 _gp. 325-32 |
|
| 999 |
_c18635751 _d18635751 |
||